Peptide PilotPeptide Pilot

Dose calculator

Sermorelin dose calculator

Convert any Sermorelin dose into syringe units in real time, pre-filled with a 5 mg / 2 mL example.

Download Peptide PilotiPhone · Free to download

Draw on a U-100 syringe

0.01 units

Volume to draw

0.000 mL

Sermorelin is a daily evening injection people use to bump up their own natural growth hormone production, usually for sleep quality, recovery, and skin and body-composition changes. It's a shortened version of the body's GHRH signal, so it nudges the pituitary instead of replacing GH from outside. Clinical studies in adults show modest but measurable IGF-1 increases over months of nightly use. This page covers reconstitution math and nightly logging cadence.

How the Sermorelin dose calculator works

This calculator answers a simple question: given the concentration of the Sermorelin solution already in your vial, how many syringe units does today's dose work out to? It is the second half of the reconstitution math — the first half locks in concentration, this one converts any dose mg or mcg into a clean unit count.

The formula is volume in mL equals dose mg divided by concentration mg/mL, then volume times one hundred to get units on a U-100 insulin syringe. With a 2.5 mg/mL Sermorelin solution and a 0.2 mg dose, the draw is 0.08 mL or about 8 units. Type any other dose and the unit count updates in real time — no spreadsheets, no guesswork.

Inputs that genuinely matter: concentration (which only changes when you reconstitute a new vial) and dose mass. Syringe type matters too, but only because U-100 vs U-40 changes the multiplier — almost every modern insulin syringe is U-100, which is why the math defaults to that. Edge cases worth flagging: switching from mcg to mg without checking the input unit, or carrying yesterday's unit count over to a new vial that was reconstituted with a different volume of BAC water.

Most people use this calculator at two moments: when titrating a dose up or down, and when prepping a single dose before injection. The output is meant to be checked against the syringe before drawing — read the markings, confirm the unit count, then draw. The calculator is fast precisely so you can do that check every time without it feeling like a chore.

How Sermorelin dosing is tracked

Research protocols for Sermorelin are built around its very short half-life and the body's natural circadian rhythm of GH secretion. Administration is frequently scheduled as a single subcutaneous injection per day, timed shortly before bedtime. This approach is intended to have the peptide's activity coincide with the largest natural GH pulse of the day, which occurs during the first few hours of slow-wave sleep. The goal is to augment this existing nocturnal pulse rather than to create an independent secretory event at another time.

A U-100 insulin syringe is the instrument typically used for subcutaneous administration, with the cadence in example protocols often set at seven times per week for consistency. The choice of a pre-sleep injection time is a deliberate strategy to align the peptide's stimulus with the body's endogenous endocrine schedule. The entire protocol structure is designed around Sermorelin's identity as a short-acting GHRH mimetic, leveraging its rapid onset and clearance to work in concert with natural pituitary function.

Protocols detailed in published literature frequently document a specific administration cadence tied to the sleep cycle. A common approach studied involves a single daily administration scheduled immediately before bedtime. This timing is methodically chosen to coincide with the body's primary endogenous GH pulse, which occurs during the first few hours of deep sleep. For personal data tracking purposes, documenting the precise time of administration relative to sleep onset is a critical variable to record. For instance, an individual following a daily cadence might calculate a 200 mcg illustrative dose from a 5 mg vial reconstituted with 2 mL, which involves drawing 0.08 mL or 8 units on a U-100 syringe.

Sermorelin mechanism in plain English

Sermorelin functions by binding to and stimulating the growth hormone-releasing hormone receptor (GHRHR) located on somatotroph cells in the anterior pituitary. This action directly mimics the physiological role of endogenous GHRH. Activation of the GHRHR initiates a signaling cascade that results in the synthesis and subsequent release of the pituitary's own stored growth hormone (GH). Because Sermorelin is cleared from the body rapidly, the resulting GH release is a discrete pulse, a characteristic often described as 'pulse-preserving'. This mechanism is fundamentally different from direct GH administration, which creates sustained, non-pulsatile levels of the hormone.

The functional mechanism of sermorelin can also be viewed through the lens of circadian biology. As a GHRH analog, it stimulates pituitary somatotrophs to release growth hormone, but the timing of this stimulation in research protocols is often deliberate. The body’s most significant endogenous GH pulse occurs during the initial phase of slow-wave sleep early in the nightly sleep cycle. Research protocols often explore administration just before this period to study how the peptide interacts with the body's peak natural pituitary activity. This allows observers to document how sermorelin's mechanism integrates with a pre-existing physiological rhythm.

Common Sermorelin dose mistakes

  • Mistaking its short half-life for a lack of activity and consequently attempting to use multi-day dosing intervals.
  • Dosing in the morning, which works against the body's natural GH circadian rhythm and the peptide's designed function.
  • Assuming it operates identically to longer-acting GHRH analogs and failing to maintain a rigid nightly administration schedule.
  • Using a very low diluent volume, such as 0.5 mL, which makes the accurate measurement of a typical 200 mcg dose exceedingly difficult on a U-100 syringe.
  • Neglecting to document the precise time of evening administration, which makes it impossible to audit adherence to the pre-sleep protocol later.
  • Misattributing the 2008 discontinuation of the commercial product Geref Diagnostic to safety problems, when public records show it was for commercial reasons related to sales volume.
  • Failing to document the precise administration time relative to sleep, which makes it difficult to analyze any observations in the context of the body's natural circadian GH release.
  • Assuming that any administration time of day is equivalent, thereby ignoring the body of research that specifically studies nighttime administration to coincide with slow-wave sleep.

Frequently asked questions about Sermorelin dose

Why is Sermorelin composed of only the first 29 amino acids of GHRH?
Sermorelin is structured as the N-terminal fragment of native Growth Hormone-Releasing Hormone because extensive research identified this segment as the biologically active region. These 29 amino acids are sufficient for binding to and stimulating the GHRH receptor with the same efficacy as the full 44-amino-acid hormone. The remaining C-terminal portion of the natural peptide is not required for this primary function.
What is meant by a 'pulse-preserving' stimulus in the context of Sermorelin?
This term describes how Sermorelin's rapid action and clearance imitate a natural GHRH signal from the brain. It causes a discrete, short-lived release of GH from the pituitary, after which the peptide is quickly eliminated from the system. This mechanism allows the body's own regulatory feedback loops and subsequent natural GH pulses to function without interference, in contrast to the sustained hormone levels produced by direct GH administration.
Why is Sermorelin's dosing schedule typically set for right before bed?
The human body's most significant natural surge of GH occurs during the early stages of deep sleep, shortly after nightfall. By scheduling a Sermorelin dose immediately before sleep, the peptide's peak action is timed to coincide with this powerful natural event. This strategy aims to amplify the body's own largest GH pulse instead of generating a separate pulse at a non-physiological time.
With a 5 mg vial and 2 mL of diluent, how many units is a 200 mcg dose?
When a 5 mg vial of powder is reconstituted with 2 mL of bacteriostatic water, the resulting solution has a concentration of 2,500 mcg per mL. To draw a 200 mcg dose, the calculated volume is 0.08 mL. On a U-100 insulin syringe, this volume corresponds exactly to the 8-unit mark.
Is the very short half-life of Sermorelin considered a disadvantage?
Its short half-life, estimated at 10 to 20 minutes, is a defining functional characteristic rather than an inherent flaw. This rapid clearance is precisely what enables Sermorelin to produce a brief, pulsatile stimulus that closely mimics the body's natural GHRH signaling pattern. Other analogs with longer half-lives produce a more sustained stimulation, which represents a fundamentally different mechanism of action and physiological effect.
Given its age, has research on Sermorelin been superseded by newer analogs?
While newer GHRH analogs with different properties now exist, Sermorelin's extensive history since the 1970s provides an exceptionally deep catalog of research data. Its former status as an FDA-approved drug means it has been rigorously studied for its specific pulsatile mechanism. It remains a valuable reference compound for understanding GHRH receptor pharmacology and the physiological response to short-acting stimuli.
Why is sermorelin administration often studied with a bedtime dosing schedule?
Research protocols often schedule sermorelin administration before sleep to align with the body's natural circadian rhythm. The largest and most predictable pulse of endogenous growth hormone (GH) occurs during the first period of slow-wave sleep, typically within the initial hours after sleep onset. Studies aiming to observe the effects of augmenting this natural pulse therefore time the administration accordingly. This allows researchers to document the peptide's interaction with the body’s existing hormonal architecture.
Was the sermorelin-based product Geref taken off the market for safety reasons?
No, the discontinuation of Geref Diagnostic by its manufacturer, EMD Serono, in 2008 was publicly stated to be for commercial reasons. The product was approved as a diagnostic agent, and low market demand made its continued production financially unviable for the company. The decision was not driven by safety or efficacy issues with sermorelin itself, a point that is critical for accurately documenting its history.
What is the structural relationship between sermorelin and the body's own GHRH?
Sermorelin is a synthetic peptide that represents a fragment of the native human Growth Hormone-Releasing Hormone (GHRH). Specifically, it is composed of the first 29 amino acids of the full 44-amino-acid GHRH molecule. Scientific studies identified this 1-29 segment as the biologically active portion of the hormone responsible for its function. Therefore, sermorelin is documented as a direct GHRH analog because it directly mimics the functional part of the endogenous hormone.

Related on Peptide Pilot

Log every Sermorelin dose in the app

Download on the App Store
Get the App